ozone alongside radiotherapy associated with 8-month median survival vs. 6 months in comparison group
Ozonetherapy administered during radiotherapy was associated with a median overall survival of 8 months in advanced head and neck cancer patients, comparable to the 6-month median survival in the chemotherapy group despite worse baseline prognostic features in the ozone group.
What this means for you
This finding suggests that ozone, when used alongside radiotherapy, was associated with comparable or slightly longer survival times in a seriously ill group — even though that group started with worse health indicators. While this is early-stage research and not a basis for any health decision, it points to ozone's potential role in supporting the body during physiological stress.
The published research
This page describes a documented finding about the underlying wellness technology. It is not a marketing claim about any specific device. For information about HOCATT specifically, visit hocatt.com.